Targeting STAT3 Enzyme for Cancer Treatment

被引:0
|
作者
Arun, Sowmiya [1 ]
Patel, Praveen Kumar [1 ]
Lakshmanan, Kaviarasan [2 ]
Rajangopal, Kalirajan [1 ]
Swaminathan, Gomathi [1 ]
Byran, Gowramma [1 ]
机构
[1] JSS Acad Higher Educ & Res, Dept Pharmaceut Chem, JSS Coll Pharm, Nilgiris 643001, Tamil Nadu, India
[2] Satyabhama Inst Sci & Technol, Sch Pharm, Dept Pharmaceut Chem, Chennai, Tamil Nadu, India
关键词
STAT3; inhibitors; SH-2; domain; proliferation; phosphorylation; hematological malignancies; tyrosine residue; NF-KAPPA-B; SIGNAL TRANSDUCER; TRANSCRIPTION; 3; KEY REGULATOR; EXPRESSION; ACTIVATOR; COMMUNICATION; SUPPRESSOR; APOPTOSIS; REVEALS;
D O I
10.2174/0113895575254012231024062619
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A category of cytoplasmic transcription factors called STATs mediates intracellular signaling, which is frequently generated at receptors on cell surfaces and subsequently sent to the nucleus. STAT3 is a member of a responsible for a variety of human tumor forms, including lymphomas, hematological malignancies, leukemias, multiple myeloma and several solid tumor types. Numerous investigations have demonstrated constitutive STAT3 activation lead to cancer development such as breast, head and neck, lung, colorectal, ovarian, gastric, hepatocellular, and prostate cancers. It's possible to get a hold of the book here. Tumor cells undergo apoptosis when STAT3 activation is suppressed. This review highlights the STAT3 activation and inhibition which can be used for further studies.
引用
收藏
页码:1252 / 1261
页数:10
相关论文
共 50 条
  • [41] Targeting STAT3 by a small molecule suppresses pancreatic cancer progression
    Chen, Huang
    Bian, Aiwu
    Yang, Lian-fang
    Yin, Xuan
    Wang, Jie
    Ti, Chaowen
    Miao, Ying
    Peng, Shihong
    Xu, Shifen
    Liu, Mingyao
    Qiu, Wen-Wei
    Yi, Zhengfang
    ONCOGENE, 2021, 40 (08) : 1440 - 1457
  • [42] Oridonalogs reverse chemoresistance in breast cancer cells by targeting STAT3
    Liu, Xi
    Wen, Yefei
    Kim, Hyejin
    Wang, Pingyuan
    Chen, Haiying
    Hu, Mingdao
    Ding, Ye
    Zhou, Jia
    Shen, Qiang
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Combined Treatment Targeting HIF-1α and Stat3 is a Potent Strategy for Prostate Cancer Therapy
    Reddy, Kavitha Ramasamy
    Guan, Yongli
    Qin, Guoting
    Zhou, Zhou
    Jing, Naijie
    PROSTATE, 2011, 71 (16): : 1796 - 1809
  • [44] Targeting STAT3 and NF-κB Signaling Pathways in Cancer Prevention and Treatment: The Role of Chalcones
    Krajka-Kuzniak, Violetta
    Belka, Marta
    Papierska, Katarzyna
    CANCERS, 2024, 16 (06)
  • [45] Targeting Cancer Stem Cells With Combined Inhibition of MEK and STAT3 in Pancreatic Cancer
    Roberts, C.
    Vansaun, M.
    Lamichhane, P.
    Messaggio, F.
    Kovacs, K.
    Nagathihalli, N.
    Merchant, N.
    PANCREAS, 2016, 45 (10) : 1534 - 1535
  • [46] Targeting STAT3: A crucial modulator of sepsis
    Lei, Wangrui
    Liu, Dianxiao
    Sun, Meng
    Lu, Chenxi
    Yang, Wenwen
    Wang, Changyu
    Cheng, Ye
    Zhang, Meng
    Shen, Mingzhi
    Yang, Zhi
    Chen, Yin
    Deng, Chao
    Yang, Yang
    JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (11) : 7814 - 7831
  • [47] Targeting STAT3 signaling in kidney disease
    Pace, Jesse
    Paladugu, Praharshasai
    Das, Bhaskar
    He, John C.
    Mallipattu, Sandeep K.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 316 (06) : F1151 - F1161
  • [48] STAT3 and its targeting inhibitors in osteosarcoma
    Liu, Yun
    Liao, Shijie
    Bennett, Samuel
    Tang, Haijun
    Song, Dezhi
    Wood, David
    Zhan, Xinli
    Xu, Jiake
    CELL PROLIFERATION, 2021, 54 (02)
  • [49] Therapeutic targeting of STAT3 in nasopharyngeal carcinoma
    Hui, Shinyee
    Lo, Kwok Wai
    Liu, Alyssa Ming-Ting
    Law, Marcus Hung-Nam
    Ng, Linda Wing-Chi
    Li, Peter Tin-Chung
    Cheung, Siu Tim
    CANCER RESEARCH, 2020, 80 (16)
  • [50] STAT3 targeting in dystrophic epidermolysis bullosa
    Mittapalli, V. R.
    Kuehl, T.
    Kuzet, S. E.
    Gretzmeier, C.
    Kiritsi, D.
    Gaggioli, C.
    Bruckner-Tuderman, L.
    Nystroem, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (05) : 1279 - 1281